Company Filing History:
Years Active: 2011-2017
Title: Per-Olof Fredrik Eriksson: Innovator in Therapeutic Antibody Development
Introduction
Per-Olof Fredrik Eriksson is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of therapeutic antibodies, particularly in relation to interleukin-4 receptor alpha (IL-4Rα). With a total of 4 patents, Eriksson's work focuses on innovative methods for treating disorders associated with IL-4Rα, IL-4, and IL-13.
Latest Patents
Eriksson's latest patents include groundbreaking methods for binding members of the interleukin-4 receptor α (IL-4Rα). These patents detail binding members, especially antibody molecules, that target IL-4Rα and their therapeutic applications. His work aims to address disorders such as asthma and chronic obstructive pulmonary disease (COPD), showcasing the potential of his inventions in improving patient outcomes.
Career Highlights
Throughout his career, Eriksson has been associated with Medimmune Limited, where he has furthered his research and development efforts. His expertise in therapeutic antibodies has positioned him as a key figure in the biotechnology sector, contributing to advancements in treatment methodologies.
Collaborations
Eriksson has collaborated with notable colleagues, including Karin Von Wachenfeldt and Claire Louise Dobson. These partnerships have enhanced the scope and impact of his research, fostering innovation in the field of immunology.
Conclusion
Per-Olof Fredrik Eriksson's contributions to the development of therapeutic antibodies represent a significant advancement in medical science. His innovative patents and collaborations continue to pave the way for new treatments for serious health conditions.